Advice

following an abbreviated submission:

fluticasone propionate/formoterol fumarate (flutiform®) is accepted for use within NHSScotland.

Indication under review: the regular treatment of asthma in children aged 5 to 12 years where the use of a combination product (an inhaled corticosteroid and a long-acting β2 agonist) is appropriate:

  • for patients not adequately controlled with inhaled corticosteroids and 'as required' inhaled short-acting β2 agonist.
    or
  • for patients already adequately controlled on both an inhaled corticosteroid and a long-acting β2 agonist.

SMC has previously accepted fluticasone propionate/formoterol fumarate for use in adults and adolescents aged 12 years and above with asthma where the use of a combination product is appropriate.

Download detailed advice441KB (PDF)

Download

Medicine details

Medicine name:
fluticasone/formoterol (Flutiform)
SMC ID:
SMC2178
Indication:
For the licence extension of low strength flutiform (50/5 µg) in children aged 5 to <12 years. This fixed-dose combination of fluticasone propionate and formoterol fumarate (flutiform inhaler) is indicated in the regular treatment of asthma where the use of a combination product (an inhaled corticosteroid and a long-acting β2 agonist) is appropriate: o For patients not adequately controlled with inhaled corticosteroids and ‘as required’ inhaled short-acting β2 agonist. Or o For patients already adequately controlled on both an inhaled corticosteroid and a long-acting β2 agonist. flutiform 50 microgram/5 microgram inhaler is indicated in adults, adolescents and children aged 5 years and above.
Pharmaceutical company
Napp Pharmaceuticals Ltd
BNF chapter
Respiratory system
Submission type
Abbreviated
Status
Accepted
Date advice published:
10 June 2019